Evidence map›Paper›PMID 31280217›Full record

ArticleIn vivo (Athens, Greece)

Association Between hsa-miR-30e Polymorphisms and Sporadic Primary Hyperparathyroidism Risk.

Maria Mizamtsidi, Konstantinos Nastos, Fausto Palazzo, Vasilis Constantinides, Roberto Dina, Megan Farenden, George Mastorakos, Ioannis Vassiliou, Maria Gazouli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maria MizamtsidiEndocrine Surgery Unit, Second Department of Surgery, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece maria_mizamtsidi1@yahoo.gr.
Konstantinos NastosEndocrine Surgery Unit, Second Department of Surgery, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Fausto PalazzoDepartment of Thyroid and Endocrine Surgery, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, U.K.
Vasilis ConstantinidesDepartment of Thyroid and Endocrine Surgery, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, U.K.
Roberto DinaDepartment of Pathology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, U.K.
Megan FarendenLaboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
George MastorakosUnit of Endocrinology, Diabetes and Metabolism, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Ioannis VassiliouEndocrine Surgery Unit, Second Department of Surgery, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Maria GazouliLaboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimAlmost 15% of patients with sporadic primary hyperparathyroidism (sPHPT) present with multiple gland disease (MGD). The aim of this study was to investigate the potential role of two polymorphisms of the hsa-miR-30e, in sPHPT tumorigenesis. PATIENTS AND

methodsOne-hundred twenty sPHPT patients, 77 presenting a single adenoma and 43 with MGD, and 54 healthy controls were genotyped. The SNPs were identified using the allele-specific PCR methodology, while the hsa-miR-30e expression was analyzed by real-time quantitative reverse transcriptase PCR.

resultsHsa-miR-30e expression was found to be significantly higher in patients with MGD compared to patients with single adenomas (p=0.0019), but no differences were found regarding specific genotype carriers. The genotype frequencies for ss178077483 and rs7556088 were significantly different between patients and healthy controls.

conclusionAlthough the polymorphisms cannot be used as biomarkers for the differential diagnosis of MGD, hsa-miR-30e expression could potentially serve as a biomarker for this purpose.

Indexed as

Genetic Association StudiesGenetic Predisposition to DiseasePolymorphism, Single NucleotideAdolescentAdultAgedAllelesBiomarkersCase-Control StudiesFemaleGene Expression Regulation, NeoplasticGene FrequencyGenotypeHumansHyperparathyroidism, PrimaryMaleBiomarkersMicroRNAsMIRN30b microRNA, humanadenomamicroRNAmultiple gland diseaseSporadic primary hyperparathyroidism

Identifiers

PMID31280217
PMCPMC6689336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.